Contrast Agents/Media Global Market – Forecast To 2025

Published by IQ4I on 8th October 2018 | Ref: 1065414 | This Report Is In Stock

$4950 | Single User
$6750 | Site License
$9000 | Enterprise License
$4950 | Single User
$6750 | Site License
$9000 | Enterprise License

Introduction

Chemical substances that improve the visibility of specific organs, tissues or blood vessel during a diagnostic imaging investigation are known as contrast agents. These substances are administered directly through veins, arteries, and joints or consumed orally. X-ray and computed tomography (CT) imaging exams makes use of iodinated and barium based contrast agents, whereas, Gadolinium-based contrast agents are preferred in MRI (Magnetic Resonance Imaging). These substances improve the reporting or accuracy of how internal structures of body are working and any associated abnormalities. Ultrasound scans makes use of special contrast agents called microbubbles which strongly interact with the ultrasound beam and enhances the details of heart, liver and kidney.

As estimated by IQ4I Research, the contrast agent global market is expected to grow at single digit CAGR to reach ,879.0 million by 2025. The contrast agent global market by molecule is segmented into Iodine based [Ionic (Monomeric and Dimeric), Non-Ionic (Monomeric and Dimeric)], Gadolinium-based contrast agents [Macrocyclic (Ionic and Non-Ionic), Linear (Ionic and Non-Ionic)], microbubble based contrast agent and others which include Barium, iron and dyes. Iodine-based contrast agent market held the largest market revenue in 2018 and microbubble segment is growing rapidly at double digit CAGR from 2018 to 2025 due to expansion in disease indications. Based on ionicity, the Iodine-based contrast agent is segmented into ionic and non-ionic. Non-Ionic Iodine-based contrast agent market accounted the largest share. Non-ionic iodine contrast agents are used more because of lower osmolality, they are better tolerated and another advantage is that, they appear to have less toxicity. Ionic Iodine based contrasts are further segmented by its chemical structure into monomers and dimers. Monomers market accounted for the largest share. Non-Ionic Iodine based contrasts are further segmented by its chemical structure into monomeric and dimeric. Monomerics market accounted the largest share as they are safer and tolerable when compared to ionic contrast agent and low osmolar agents do not dissociate into a particle in solution and helps in reducing the neurotoxicity.

The contrast agents market by modality is segmented into X-Ray/CT, MRI and Ultrasound. X-Ray/CT market held the largest market revenue in 2018 and ultrasound segment is growing rapidly at double digit CAGR from 2018 to 2025 due to increased use in diagnostic procedures especially echocardiography, focal liver lesions and ultrasonography of urinary tract.

The contrast agents market by applications is segmented into cardiovascular, cancer, gastrointestinal, musculoskeletal, neurology, nephrology, obstetrics & gynecology, urology and others which include neck, liver and salivary gland imaging. Cardiovascular market accounted for the largest share and is the fastest growing market from 2018 to 2025 due to increase in a number of cardiac imaging procedures using Iodine, Gadolinium and microbubble contrast agents. Contrast agents market by route of administration is segmented into intravascular, oral, rectal and others which include intraosseous, intrathecal and intravesicle. Intravascular route of administration accounted for largest share and is the fastest growing market due to increase in incidence and prevalence of cardiovascular, cancer, neurology, nephrology related conditions which require Iodine, Gadolinium and microbubble contrast agent to be administered intravascular.

Contrast agents market by imaging is segmented into diagnostic and interventional imaging. Diagnostic imaging market held the largest market revenue and interventional imaging segment is growing at fast/rapidly at double digit CAGR from 2018 to 2025 due to increase in image guide procedures and increase in aging population who usually opt minimally invasive procedures.

Contrast agents market based on the end-user market is segmented into hospitals, diagnostic & ambulatory surgical centers and other which include academic and research institutes. Hospitals market accounted largest share in 2018 as there is a rise in demand for the diagnosis and interventional treatment of diseases using CT or X-Ray, MRI and ultrasound imaging procedures. Diagnostic & Ambulatory surgical centers is the fastest growing segment with mid single digit CAGR from 2018 to 2025 due to increase in number of diagnostic procedures related to musculoskeletal (arthroscopy, imaging of spine), gastrointestinal (imaging of abdomen, GI tract) and obstetrics & gynecology (hysterosalpingography).

Geographical wise, North America region commanded the largest revenue in 2018. Favorable reimbursement coverage and increase in incidence and prevalence of diseases conditions due to change in lifestyle, obesity has led the market growth in this region. However, Asia-Pacific region is the second leading market for contrast agents and is expected to grow at mid single CAGR from 2018 to 2025 due to increased healthcare awareness, economic growth, large patient pool and rising aged population.

The contrast agent global market is a competitive market and all the existing players in this market are involved in developing new and advanced products to maintain their market shares and also acquiring companies for product expansion. Some of the key players of the contrast agent market are GE Company (GE Healthcare) (U.S.), Bayer Group (Germany), Guerbet (France), Taejoon Pharm Co. Ltd., (South Korea), Beijing Beilu Pharmaceuticals Company Limited (China), Bracco Group (Italy), Fujifilm Holding Corporation (Japan), Sanochemia Pharmazeutika AG (Austria), Dongkook Lifescience (Korea), Lantheus medical imaging (U.S.) and Fujipharma Co. Ltd (Japan).

The report provides an in-depth market analysis of the above-mentioned segments across the following regions:

• North America

• Europe

• Asia-Pacific

• Rest of the World (RoW)

Table of Contents

1 EXECUTIVE SUMMARY 26

2 INTRODUCTION 31

2.1 KEY TAKEAWAYS 31

2.2 REPORT SCOPE 32

2.3 REPORT DESCRIPTION 32

2.4 MARKETS COVERED 35

2.5 STAKEHOLDERS 37

2.6 RESEARCH METHODOLOGY 37

3 MARKET ANALYSIS 46

3.1 INTRODUCTION 46

3.2 MARKET SEGMENTATION 46

3.3 FACTORS INFLUENCING MARKET 48

3.4 REGULATORY GUIDELINES 57

3.5 REIMBURSEMENT SCENARIO 61

3.6 UPCOMING TECHNOLOGY 65

3.7 CLINICAL TRIALS 70

3.8 PATENT TRENDS 71

3.9 SUPPLY CHAIN ANALYSIS 73

3.10 PORTER’S FIVE FORCE ANALYSIS 76

3.11 MARKET SHARE ANALYSIS BY MAJOR PLAYERS 79

3.12 CONTRAST AGENT GLOBAL CONSUMPTION 89

4 CONTRAST AGENTS GLOBAL MARKET, BY MOLECULE 94

4.1 INTRODUCTION 94

4.2 IODINE BASED CONTRAST MEDIA 96

4.3 GADOLINIUM-BASED CONTRAST MEDIA 114

4.4 MICROBUBBLE BASED CONTRAST MEDIA 127

4.5 OTHER CONTRAST MEDIA 130

5 CONTRAST AGENTS GLOBAL MARKET, BY MODALITY 134

5.1 INTRODUCTION 134

5.2 X-RAY/COMPUTED TOMOGRAPHY (CT) 137

5.3 MAGNETIC RESONANCE IMAGING (MRI) 138

5.4 ULTRASOUND 140

6 CONTRAST AGENTS GLOBAL MARKET, BY APPLICATION 142

6.1 INTRODUCTION 142

6.2 CARDIOVASCULAR 145

6.3 CANCER 149

6.4 GASTROINTESTINAL 151

6.5 MUSCULOSKELETAL 154

6.6 NEUROLOGY 157

6.7 NEPHROLOGY 159

6.8 OBSTETRICS AND GYNECOLOGY 162

6.9 UROLOGY 165

6.10 OTHERS 168

7 CONTRAST AGENTS GLOBAL MARKET, BY ROUTE OF ADMINISTRATION 171

7.1 INTRODUCTION 171

7.2 INTRAVASCULAR 174

7.3 ORAL 177

7.4 RECTAL 180

7.5 OTHERS 183

8 CONTRAST AGENTS GLOBAL MARKET, BY IMAGING 186

8.1 INTRODUCTION 186

8.2 DIAGNOSTIC IMAGING 189

8.3 INTERVENTIONAL IMAGING 192

9 CONTRAST AGENT GLOBAL MARKET, BY END-USERS 195

9.1 INTRODUCTION 195

9.2 HOSPITAL 198

9.3 DIAGNOSTIC & AMBULATORY SURGICAL CENTERS 201

9.4 OTHER END-USER 204

10 REGIONAL ANALYSIS 207

10.1 INTRODUCTION 207

10.2 NORTH AMERICA 212

10.3 EUROPE 240

10.4 ASIA-PACIFIC 278

10.5 REST OF THE WORLD 317

11 COMPETITIVE LANDSCAPE 350

11.1 INTRODUCTION 350

11.2 APPROVALS 351

11.3 OTHER KEY DEVELOPMENT 355

11.4 COLLABORATION 357

11.5 PARTNERSHIP 357

11.6 AGREEMENT 358

11.7 NEW PRODUCT LAUNCH 359

12 MAJOR PLAYER PROFILES 361

12.1 BAYER GROUP 361

12.2 BEIJING BEILU PHARMACEUTICAL CO., LTD 367

12.3 BRACCO GROUP 370

12.4 DONGKOOK LIFE SCIENCE 377

12.5 FUJIFILM HOLDINGS CORPORATION 380

12.6 FUJIPHARMA CO LTD 386

12.7 GE COMPANY (GE HEALTHCARE) 391

12.8 GUERBET 397

12.9 LANTHEUS MEDICAL IMAGING INC. 404

12.10 SANOCHEMIA PHARMACEUTICAL AG 409

12.11 TAEJOON PHARM CO., LTD 413

Additional Details

Publisher

IQ4I

Publisher Information

Reference

1065414 |

Number of Pages

415

Report Format

PDF

This report is published by IQ4I

Download Free Report Summary PDF

Contrast Agents/Media Global Market – Forecast To 2025 [Updated: 08-10-2018] | Download PDF Summary

Download our FREE report summary PDF. It contains all the information on these web pages, plus a Proforma Invoice request form, should you need it to satisfy your company's internal order procedures.

Ordering Information

Orders are processed immediately and you will be notified of the despatch date on confirmation of your order.

Accepted Card Types

Payment

Buy now using our secure payment system.